Mylan has announced that it has received final approval from the US FDA for its Abbreviated New Drug Application (ANDA) for the generic version of Novartis' Myfortic (mycophenolic acid) 180 mg and 360 mg delayed-release tablets in the United States. As a result, the company has proceeded to launch the drug indicated for the prevention of organ rejection in adults and paediatric patients aged five or older following kidney transplants.